Cargando…
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
SIMPLE SUMMARY: Kidney cancer has many forms, which fall under the overall term, renal cell carcinoma. Clear cell renal cell carcinoma is by far the most common type, and all other renal cell carcinomas are categorized as non-clear cell renal cell carcinoma. Patients with non-clear cell renal cell c...
Autores principales: | Zarrabi, Kevin, Walzer, Emily, Zibelman, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344970/ https://www.ncbi.nlm.nih.gov/pubmed/34359554 http://dx.doi.org/10.3390/cancers13153652 |
Ejemplares similares
-
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022) -
Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
por: Watanabe, Kazuhiro, et al.
Publicado: (2021) -
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
por: Yu, Eun-mi, et al.
Publicado: (2021) -
Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
por: He, Shengxiu, et al.
Publicado: (2023) -
Neoadjuvant checkpoint inhibition in renal cell carcinoma associated Stauffer's syndrome
por: Zarrabi, Kevin, et al.
Publicado: (2019)